[go: up one dir, main page]

MX2019009642A - Formulaciones. - Google Patents

Formulaciones.

Info

Publication number
MX2019009642A
MX2019009642A MX2019009642A MX2019009642A MX2019009642A MX 2019009642 A MX2019009642 A MX 2019009642A MX 2019009642 A MX2019009642 A MX 2019009642A MX 2019009642 A MX2019009642 A MX 2019009642A MX 2019009642 A MX2019009642 A MX 2019009642A
Authority
MX
Mexico
Prior art keywords
formulations
surfactant
active ingredient
methods
cannabinoid
Prior art date
Application number
MX2019009642A
Other languages
English (en)
Inventor
Yucel Tuna
Stephen Faraci William
Zale Stephen
Paraskar Abhimanyu
J Boylan Nicholas
Original Assignee
Molecular Infusions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Infusions Llc filed Critical Molecular Infusions Llc
Publication of MX2019009642A publication Critical patent/MX2019009642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

La invención proporciona formulaciones de cannabinoides, que incluye formulaciones autoemulsionantes y dispersiones micelares, así como también los métodos para producirlas y usarlas. Las formulaciones comprenden un cannabinoide y un tensioactivo. Las formulaciones han mejorado la disolución, la estabilidad y la farmacocinética, incluida la absorción y/o la biodisponibilidad oral. La invención proporciona además formulaciones que comprenden al menos un ingrediente activo, que incluye formulaciones autoemulsionantes y dispersiones micelares, así como también los métodos para prepararlas y usarlas. Las formulaciones comprenden al menos un ingrediente activo y un tensioactivo.
MX2019009642A 2017-02-15 2018-02-15 Formulaciones. MX2019009642A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459086P 2017-02-15 2017-02-15
US201762546149P 2017-08-16 2017-08-16
PCT/US2018/018382 WO2018152334A1 (en) 2017-02-15 2018-02-15 Formulations

Publications (1)

Publication Number Publication Date
MX2019009642A true MX2019009642A (es) 2019-11-11

Family

ID=63169642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009642A MX2019009642A (es) 2017-02-15 2018-02-15 Formulaciones.

Country Status (10)

Country Link
US (1) US20200037638A1 (es)
EP (1) EP3582755A4 (es)
JP (1) JP2020509081A (es)
CN (1) CN110636834A (es)
AU (1) AU2018221739A1 (es)
CA (1) CA3053158A1 (es)
CO (1) CO2019009986A2 (es)
IL (1) IL268697A (es)
MX (1) MX2019009642A (es)
WO (1) WO2018152334A1 (es)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160157515A1 (en) 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
CA3043605A1 (en) * 2016-11-14 2018-05-17 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
EP3716945A4 (en) * 2017-11-30 2021-04-07 Canopy Growth Corporation LIQUID DOSAGE FORMS, METHOD OF MANUFACTURING AND USE
US11684604B2 (en) 2018-02-23 2023-06-27 Yuzu Lv Llc Cannabis based therapeutic and method of use
EP3773527A4 (en) 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES
WO2019191830A1 (en) * 2018-04-04 2019-10-10 Vincenzo Maida Topical cannabinoid formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
US11013715B2 (en) * 2018-07-19 2021-05-25 Vertosa, Inc. Nanoemulsion hydrophobic substances
US20210298340A1 (en) * 2018-08-20 2021-09-30 Hexo Operations Inc. Cannabis-Infused Product with Extended Cannabinoid Profile User Experience
CA3062141A1 (en) * 2018-08-20 2020-02-20 Hexo Operations Inc. Cannabinoid based emulsion systems for infused aqueous compositions
CA3110435A1 (en) * 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Therapeutic combinations of cannabinoids with curcumin
MX2021002440A (es) * 2018-09-21 2021-04-28 Hai Beverages Inc Composición de bebida cannabinoide soluble en agua.
PE20211198A1 (es) * 2018-10-10 2021-07-01 Tilray Inc Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
US20210361574A1 (en) * 2018-10-15 2021-11-25 New Frontier Brewing Company, Llc Nanoemulsion cannabis formulations and methods of making same
JP2022513411A (ja) * 2018-10-31 2022-02-07 ベイメディカ インコーポレイテッド カンナビノイド類似体およびそれらの調製のための方法
US20200138072A1 (en) * 2018-11-01 2020-05-07 Molecular Infusions, Llc Polymer-based oral cannabinoid and/or terpene formulations
US12491452B2 (en) 2018-12-11 2025-12-09 Naturalia Ingredients S.R.L. Extraction method and composition obtained therefrom
WO2020123407A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
EP3893868A4 (en) * 2018-12-12 2022-08-10 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN T-CELL LYMPHOMA (CTCL)
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
EP3897593A4 (en) * 2018-12-19 2022-08-24 Tilray, Inc. CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
BR112021014976A2 (pt) * 2019-02-08 2021-10-05 Schedule 1 Therapeutics, Inc. Composições compreendendo canabinoides e métodos de uso das mesmas
WO2020183455A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating low back pain
WO2020183457A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating diabetic neuropathy
EP3937915A4 (en) * 2019-03-13 2022-12-21 Milane, Michael NOVEL NANOFORMULATION OF CANNABIDIOL (CBD) AND OTHER CANNABINOIDS FOR THE TREATMENT OF SKIN DISEASES
EP3937912A4 (en) * 2019-03-13 2022-12-21 Ulagaraj Selvaraj STABILIZED SOLID NANOPARTICLE FORMULATIONS OF CANNABINOIDS AND CANNABINOID ANALOGUES WITH REDUCED OSTWALD MATURATION FOR ORAL, INHALATIVE, NASAL AND PARENTAL DELIVERY
US20220183999A1 (en) * 2019-04-05 2022-06-16 Sorrento Therapeutics, Inc. Cannabidiol Pharmaceutical Compositions
EP3968959A2 (en) * 2019-05-15 2022-03-23 Benuvia Manufacturing, LLC Self-emulsifying cannabidiol formulations
AU2020277341A1 (en) * 2019-05-20 2021-11-11 Poviva Corp. Nanoemulsion compositions comprising biologically active ingredients
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US20230226085A1 (en) * 2019-08-15 2023-07-20 Advanced NanoEmulsions Inc Surfactant compositions and methods for emulsifying cannabinoid extracts as a nano-emulsion material
US20220280444A1 (en) * 2019-08-27 2022-09-08 Natural Extraction Systems, LLC Compositions Comprising Decarboxylated Cannabinoids
WO2021046189A1 (en) * 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
CA3151836A1 (en) * 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for cannabis extracts and terpenes
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
US12342847B2 (en) 2019-09-11 2025-07-01 Nicoventures Trading Limited Oral product with cellulosic flavor stabilizer
US20210137877A1 (en) * 2019-11-07 2021-05-13 Timothy Dale Hewett Products and methods for using cannabidiol in combination with melatonin to induce sleep
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
US12137723B2 (en) 2019-12-09 2024-11-12 Nicoventures Trading Limited Oral products with active ingredient combinations
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12151023B2 (en) 2019-12-09 2024-11-26 Nicoventures Trading Limited Oral composition with beet material
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11889856B2 (en) 2019-12-09 2024-02-06 Nicoventures Trading Limited Oral foam composition
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
MX2022006982A (es) 2019-12-09 2022-09-12 Nicoventures Trading Ltd Producto oral en una bolsa porosa que comprende un material de vellon.
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12491250B2 (en) 2019-12-09 2025-12-09 Nicoventures Trading Limited Oral composition with nanocrystalline cellulose
MX2022007086A (es) 2019-12-09 2022-09-09 Nicoventures Trading Ltd Agentes para la composicion oral.
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
JP2023505800A (ja) 2019-12-09 2023-02-13 ニコベンチャーズ トレーディング リミテッド 刺激応答性パウチ
EP4072347B1 (en) 2019-12-09 2025-02-12 Nicoventures Trading Limited Fleece for oral product with releasable component
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
CA3160271A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Nanoemulsion for oral use
US11883527B2 (en) 2019-12-09 2024-01-30 Nicoventures Trading Limited Oral composition and method of manufacture
CN111956535A (zh) * 2019-12-30 2020-11-20 云南汉盟制药有限公司 一种调理剂组合物及其制备方法与应用
WO2021161205A1 (en) * 2020-02-13 2021-08-19 Eyal Research Consultants Ltd Microbial combinations with modulators of the opioid system and uses thereof
US11712059B2 (en) 2020-02-24 2023-08-01 Nicoventures Trading Limited Beaded tobacco material and related method of manufacture
JP2023515535A (ja) * 2020-02-27 2023-04-13 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド リメゲパントの経口急速分散剤形
WO2021175311A1 (zh) * 2020-03-05 2021-09-10 成都百裕制药股份有限公司 含有银杏内酯和大麻素类化合物的药物组合物及其在医药上的应用
WO2021195173A1 (en) * 2020-03-25 2021-09-30 Molecular Infusions, Llc Solid cannabinoid formulation for oral administration
MX2022012001A (es) * 2020-03-29 2022-10-21 Biohaven Pharmaceutical Ireland Dac Tratamiento preventivo de la migra?a.
WO2021202413A1 (en) * 2020-03-30 2021-10-07 Ojai Energetics Pbc Systems, methods, and compositions for infections
US20210308636A1 (en) * 2020-04-02 2021-10-07 Brian Brown Tetrahydrocannabinol emulsion and method of making and using
US12016369B2 (en) 2020-04-14 2024-06-25 Nicoventures Trading Limited Regenerated cellulose substrate for aerosol delivery device
EP4135898A4 (en) 2020-04-15 2024-05-29 Enumerix, Inc. SYSTEMS AND METHODS FOR GENERATING EMULSIONS OF APPROPRIATE CLARITY WITH APPLICATIONS OF USE
CN115843245A (zh) * 2020-05-11 2023-03-24 埃德先进药物输送技术有限责任公司 大麻素的用途和制剂
EP4149445A1 (en) * 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Uses and formulations of cannabinoids
US11975098B2 (en) * 2020-05-22 2024-05-07 Colorado School Of Mines Nanosuspensions of cannabidiol for developing water-dispersible formulations
EP4161295A1 (en) 2020-06-08 2023-04-12 Nicoventures Trading Limited Effervescent oral composition comprising an active ingredient
AU2021286489A1 (en) * 2020-06-10 2023-02-02 Corenhanced Technologies Llc Compositions for the delivery of therapeutic agents and methods of use and making thereof
BR102020023664A2 (pt) * 2020-07-02 2022-01-11 Yuzu Llc Composições compreendendo canabidiol e flavononas
US20220008378A1 (en) * 2020-07-07 2022-01-13 Jonathan Tessmar-Bell Formulations and methods
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
AU2021328452A1 (en) * 2020-08-18 2023-03-23 Leiutis Pharmaceuticals Llp Nano lipid carrier system for improving permeation of active ingredients
US20230270766A1 (en) * 2020-08-27 2023-08-31 Credo Science, Llc Methods and compositions for the treatment of als
US20220062163A1 (en) * 2020-09-01 2022-03-03 Pharmacannis Labs Llc Effervescent tablets
CN112220756B (zh) * 2020-10-16 2023-06-13 重庆市义力医药科技有限公司 一种尼古丁颗粒组合物及其制备方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230398175A1 (en) * 2020-11-09 2023-12-14 Scai Therapeutics Solid cyclosporin a and dispersion composition comprising same
WO2022098121A1 (ko) * 2020-11-09 2022-05-12 주식회사 스카이테라퓨틱스 고상의 물질 및 이를 포함하는 분산 조성물
IT202000027408A1 (it) 2020-11-16 2022-05-16 Indena Spa Dispersioni solide di cannabidiolo
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
IT202000030914A1 (it) * 2020-12-15 2022-06-15 Mario Antonio Basile Composizione farmaceutica solida di ademetionina e cannabidiolo e procedimento per ottenerla
WO2022133612A1 (en) * 2020-12-24 2022-06-30 Tetra Bio-Pharma Inc. Parenteral cannabinoid formulations and uses thereof
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技（北京）有限公司 一种水溶性大麻素制剂及其制备方法
CN114748434B (zh) * 2020-12-29 2023-06-16 汉义生物科技（北京）有限公司 一种大麻素泡腾片及其制备方法
CA3150984A1 (fr) * 2021-02-26 2022-08-26 Eleonor Composition comprenant au moins un cannabinoide non-euphorisant naturel ou synthetique et son procede de fabrication
CN117241878A (zh) 2021-03-05 2023-12-15 伊努梅里斯公司 用于生成微滴和执行数字分析的系统和方法
WO2022183480A1 (zh) * 2021-03-05 2022-09-09 成都百裕制药股份有限公司 含有银杏内酯类化合物和大麻二酚的药物组合物及其在医药上的应用
JP2024510317A (ja) 2021-03-19 2024-03-06 ニコベンチャーズ トレーディング リミテッド エアロゾルデリバリーデバイス用ビーズ状基材
CN113057940B (zh) * 2021-03-24 2022-08-19 贵州医科大学 1,8-桉叶油素乳剂及其制备方法
CN113197852B (zh) * 2021-04-20 2022-12-09 上海应用技术大学 大麻二酚纳米胶束制剂及其制备方法
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
US20220347119A1 (en) * 2021-04-30 2022-11-03 Reshma N. Kheraj Medicated drink
EP4351788A4 (en) 2021-06-04 2025-04-09 Enumerix, Inc. COMPOSITIONS, METHODS AND SYSTEMS FOR SINGLE-CELL ENCODING AND SEQUENCING
EP4358748A1 (en) 2021-06-25 2024-05-01 Nicoventures Trading Limited Oral products and method of manufacture
CN113461929B (zh) * 2021-07-13 2023-04-21 浙江倍合德制药有限公司 一种tpgs系列产品的精制提纯方法
CN119789793A (zh) 2021-07-30 2025-04-08 尼科凡图尔斯贸易有限公司 包含微晶纤维素的气溶胶发生基材
US12252745B2 (en) 2021-09-02 2025-03-18 Enumerix, Inc. Detection and digital quantitation of multiple targets
US20230081296A1 (en) * 2021-09-14 2023-03-16 Nulixir Inc. Stable non-aqueous compositions of plants extracts and methods of making the same
US20230111190A1 (en) * 2021-09-14 2023-04-13 Nulixir Inc. Oral compositions with improved bioavailability and methods of making the same
US20230111238A1 (en) * 2021-09-14 2023-04-13 Nulixir Inc. Stable compositions of functional ingredients and methods of making the same
US20250275935A1 (en) * 2021-09-17 2025-09-04 Igc Pharma Ip, Llc Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin
AU2022378758A1 (en) * 2021-10-29 2024-05-16 Aquila Black Limited Water dispersible cannabinoid compositions
EP4453246A4 (en) 2021-12-20 2025-12-24 Countable Labs Inc DIGITAL DETECTION AND QUANTIFICATION OF MULTIPLE TARGETS
JP7202440B1 (ja) * 2021-12-28 2023-01-11 第一工業製薬株式会社 組成物及びその製造方法並びに界面活性剤
LU501323B1 (en) 2022-01-25 2023-07-25 Kemijski Inst Cannabinoid complexes with improved properties
US12440455B2 (en) * 2022-02-14 2025-10-14 Impact Naturals, Inc. Methods of administering cannabinoids
CA3244771A1 (en) * 2022-02-25 2023-08-31 Sgn Nanopharma Inc. Nanoemulsions containing anti-inflammatory cannabinoids and their methods of use
WO2023159277A1 (en) * 2022-02-28 2023-08-31 Emyria Cannabinoid dosage form
JP7202492B1 (ja) 2022-03-30 2023-01-11 第一工業製薬株式会社 Ｏ／ｄ型乳化組成物
JP7216234B1 (ja) * 2022-04-20 2023-01-31 第一工業製薬株式会社 乳化組成物
CN115364050B (zh) * 2022-08-02 2023-07-18 无锡诺平医药科技有限公司 H2cbd乳液、制备方法及其药物应用
US12016359B2 (en) 2022-11-11 2024-06-25 Pharmavite Llc Oil-in-water emulsion gummy composition with water soluble active ingredient(s)
AU2023423683A1 (en) * 2023-01-11 2025-07-17 Aquanova Ag Cannabinoid solubilizate
KR20240140871A (ko) * 2023-03-17 2024-09-24 주식회사 씨티씨바이오 칸나비디올 수용액 조성물 및 이를 포함하는 칸나비디올 함유 약학 제제
US20240316072A1 (en) * 2023-03-21 2024-09-26 Unique Flower LLC Therapeutic compositions, components and methods of preparation and use thereof
CN118021721A (zh) * 2024-01-19 2024-05-14 沈阳药科大学 一种脑靶向阿戈美拉汀鼻喷胶束的制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
WO1995025504A1 (en) * 1994-03-18 1995-09-28 Pharmavene, Inc. Emulsified drug delivery systems
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
JP2003504321A (ja) * 1999-07-08 2003-02-04 オーランド・ハン リポソーム被包カンナビノイドの肺送達
US20040110828A1 (en) * 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
AU2006311818B9 (en) * 2005-11-07 2013-05-16 Murty Pharmaceuticals, Inc Improved delivery of tetrahydrocannabinol
US20160184258A1 (en) * 2005-11-07 2016-06-30 Murty Pharmaceuticals, Inc. Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
JP2010503664A (ja) * 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー．ブイ． 水不溶性医薬活性物質の舌下、頬若しくは経口投与のための医薬投薬単位
WO2012033478A1 (en) * 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
DK2804587T3 (da) * 2012-01-19 2019-08-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
CH706963B1 (de) * 2012-08-30 2016-03-31 Ai Fame Gmbh Verfahren zur Herstellung eines Cannabis enthaltenden Präparates.
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
CN105916492A (zh) * 2013-10-31 2016-08-31 全谱实验室有限公司 萜烯和大麻素制剂
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
EP3232808B1 (de) * 2014-12-19 2020-04-01 THC Pharm GmbH The Health Concept Cbd-haltiges getränk
US20160213624A1 (en) * 2015-01-23 2016-07-28 Tom Lindeman Composition, Commericial Product and Method for Treating Cannabis Toxicity
EP3268043A4 (en) * 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
WO2016147186A1 (en) * 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CN109414403A (zh) * 2016-07-11 2019-03-01 因泰克制药有限公司 口服胃滞留制剂及其用途
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation

Also Published As

Publication number Publication date
CN110636834A (zh) 2019-12-31
WO2018152334A1 (en) 2018-08-23
CO2019009986A2 (es) 2019-09-30
EP3582755A4 (en) 2020-12-23
EP3582755A1 (en) 2019-12-25
IL268697A (en) 2019-10-31
CA3053158A1 (en) 2018-08-23
JP2020509081A (ja) 2020-03-26
AU2018221739A1 (en) 2019-08-29
US20200037638A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
CO2019009986A2 (es) Formulaciones
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX373189B (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación.
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
MX2018008772A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
CO2018007535A2 (es) Análogos de cortistatina y usos de los mismos
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
MX2017011934A (es) Formas solidas de menaquinoles.
PE20170702A1 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
DK3454658T3 (da) Glyphosatformuleringer, der indeholder amidoalkylamin-overfladeaktive stoffer
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
CO2018006395A2 (es) Concentrados en emulsión de compuestos lipofílicos
CO6612200A2 (es) Fromulaciones herbicidas estabilizadas y mètodos de uso
BR112018073649A2 (pt) agente de controle de espuma de poliéter, formulação agroquímica, e, processo para preparar uma formulação agroquímica.
BR112017025994A2 (pt) formulações de oxima de ciclo-hexanodiona estabilizadas com tensoativo